Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-06835919 + atorvastatin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-06835919 + atorvastatin is an investigational oral combination of PF-06835919, a first-in-class ketohexokinase inhibitor developed by Pfizer, and atorvastatin, a well-established HMG-CoA reductase inhibitor (statin). PF-06835919 inhibits ketohexokinase (KHK), thereby suppressing hepatic fructose phosphorylation and showing reductions in liver fat in metabolic disorders such as non-alcoholic fatty liver disease, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease[2][3][4][5][6][7]. Atorvastatin lowers cholesterol via inhibition of HMG-CoA reductase to reduce LDL-C and cardiovascular risk. This combination is studied to evaluate pharmacokinetic interactions, safety, and efficacy, particularly the effect of PF-06835919 on OATP1B1 activity that may impact atorvastatin metabolism[3]. The combination is undergoing clinical investigation, notably for metabolic diseases and the related risk of drug-drug interaction due to transporter modulation.
- Other names
- PF-06835919 + atorvastatin
02
Targets
OATP1B1 (Organic anion transporting polypeptide 1B1)KHK-C (Ketohexokinase C)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on PF-06835919 + atorvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-06835919 + atorvastatin.